Adjudication of Self-reported Symptomatic Stone Recurrence in the Prevention of Urinary Stones With Hydration Trial
- PMID: 39242045
- PMCID: PMC11625008
- DOI: 10.1016/j.urology.2024.08.026
Adjudication of Self-reported Symptomatic Stone Recurrence in the Prevention of Urinary Stones With Hydration Trial
Abstract
Objective: To assess accuracy of self-reported stone events in a large clinical trial by adjudication against the weight of documentation for spontaneous stone passage or surgical intervention.
Methods: Participants in the Prevention of Urinary Stones with Hydration (PUSH) trial were randomized to a multi-component behavioral intervention or control arm to increase and maintain high fluid intake. The primary endpoint was urinary stone events including symptomatic stone passage or procedural intervention. An independent adjudication committee blinded to randomization assignments reviewed all events. Confirmed clinical stone events required typical stone symptoms and documentation of stone passage (eg, via photograph, clinical record) and/or surgical intervention. Events with typical symptoms and self-described stone passage but without objective documentation of passage were also considered as meeting the primary endpoint and classified separately as patient-reported passage. Non-events did not meet either criteria.
Results: At time of this blinded analysis, a total of 1658 participants were randomized and had a median follow-up of 19 months. Self-reported stone events (n = 217) were adjudicated by the committee as either confirmed clinical events (134; 61.8%), patient-reported passage (71; 32.7%), or non-events (12; 5.5%). Confirmed clinical events consisted of stone passage in 66/134 and procedural interventions in 68/134 (53 for symptoms and 15 without symptoms).
Conclusion: Rigorous adjudication revealed that self-reported stone events in the PUSH trial overwhelmingly represented clinically documented passage, surgical intervention, and patient-reported passage outside healthcare settings, with only 5.5% failing to satisfy adjudication criteria. Similar adjudication and classification processes warrant consideration for implementation in future stone trials.
Clinical trials registration: NCT03244189.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lai: Consultant for Medtronic, Neuspera, Allergan, Teva. Reese: Disclosures related to the submitted work: Associate editor at the American Journal of Kidney Diseases; disclosures outside of the submitted work: investigator-initiated grants from Merck and AbbVie to the University of Pennsylvania to support research on transplantation of HCV-infected organs into uninfected recipients, followed by antiviral treatment; investigator-initiated grants from CVS Caremark and Merck to the University of Pennsylvania to support research on medication adherence (focus: statins); consulting with COllaborative Healthcare Research & Data Analytics (COHRDATA) on epidemiology of medications to improve laboratory parameters including potassium among dialysis patients. Scales: Scientific Advisory Board for Lilac Therapeutics. Tasian: Scientific Advisory Board for Novo Nordisk and Alnylam Pharmaceuticals. No other potentially relevant disclosures were reported.
Figures
References
-
- Held C, White HD, Stewart RAH, Davies R, Sampson S, Chiswell K, Silverstein A, Lopes RD, Heldestad U, Budaj A, Mahaffey KW, Wallentin L; STABILITY Investigators. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J 2019. Feb;208:65–73. - PubMed
-
- Walter SD, de Koning HJ, Hugosson J, Talala K, Roobol MJ, Carlsson S, Zappa M, Nelen V, Kwiatkowski M, Páez Á, Moss S, Auvinen A; ERSPC Cause of Death Committees. Impact of cause of death adjudication on the results of the European prostate cancer screening trial. Br J Cancer. 2017. Jan 3;116(1):141–148. - PMC - PubMed
-
- Pickard R, Starr K, MacLennan G, Lam T, Thomas R, Burr J, McPherson G, McDonald A, Anson K, N’Dow J, Burgess N, Clark T, Kilonzo M, Gillies K, Shearer K, Boachie C, Cameron S, Norrie J, McClinton S. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015. Jul 25;386(9991):341–9. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
